A bill signed by President Trump on Nov. 12 – the same day he approved a conference report on the National Defense Authorization Act (NDAA) – clarifies that FDA has the authority to authorize additional emergency uses by the US military for medical products used during war time, or as agents of war.
H.R. 4374 calls on the Secretary of Defense to request a fast-track review from FDA of any medical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?